Related Experiment Videos
[Molecular markers in breast cancer: practical aspects and morphologic evaluation]
1Service d'Anatomie Pathologique, Centre Hospitalo-Universitaire de la Timone (Unité DRED EA 875-Oncogenèse des tumeurs solides), Marseille.
Bulletin De L'Academie Nationale De Medecine
|March 1, 1994
Summary
Molecular marker evaluation in breast cancer uses histochemistry and immunocytochemistry. Standardized immunocytochemistry provides crucial prognostic data for selecting patients for adjuvant therapy.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Context:
- Breast carcinomas require molecular marker assessment for diagnosis and treatment.
- Histochemistry and immunocytochemistry are established methods for evaluating these markers.
Purpose:
- To outline the utility of histochemistry and immunocytochemistry in assessing molecular markers in breast carcinomas.
- To highlight the importance of immunocytochemistry for prognostic evaluation and patient selection.
Summary:
- Molecular markers in breast cancer are assessed via histochemistry (ploidy, AgNORs) and immunocytochemistry (Ki67, cathepsin D, pHER-2/neu, EGFR, ER, PR, pS2, p53).
- Immunocytochemistry offers valuable data, especially for small tumors, complementing traditional histology.
- Standardization of immunocytochemical assays (frozen sections, image analysis) is essential for clinical application.
Impact:
- Provides additional data for prognostic evaluation in breast cancer.
- Aids in selecting node-negative patients who may benefit from adjuvant therapy.
- Emphasizes the need for standardized methods to ensure reliable clinical use of immunocytochemistry.